Advancing the Manufacturing of Biological Therapeutics and Vaccines

A special issue of Biology (ISSN 2079-7737).

Deadline for manuscript submissions: closed (15 December 2020) | Viewed by 7145

Special Issue Editors


E-Mail Website
Guest Editor
Department of Chemical Engineering, University of Massachusetts, Lowell, MA 01854, USA
Interests: Process Analytical Technology (PAT) and Quality by Design (QbD); experimental design and multivariate data analysis; bigdata analytics; systems biology; pharmacometrics; pharmaceutical process modeling and simulation
Special Issues, Collections and Topics in MDPI journals
Center for Biomedical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02142, USA
Interests: bioprocess development; viral vector; biological systems; quality control

Special Issue Information

Dear Colleagues,

Biological therapies are under rapid development and show paramount importance in human health and public health at this time of a worldwide pandemic. Monoclonal antibody, cell therapy, gene therapy, and vaccine are among the therapy that have rapidly developed in recent years, witnessing thousands of molecules entering clinical trials. These biologics have various forms, including recombinant proteins, viral vector, RNA, and many other modalities. 

Manufacturing processes of these biologics need process engineering, which involves production in a biosystem, purification by physicochemical properties, and analytics that help to understand processes and products. Biomanufacturing processes are challenged by an unmet need to improve process efficiency and control of product quality. Common problems include scale-up, process and product variabilities, suboptimal yields, difficult development, and insufficient process understanding. The key to advancing biomanufacturing is through fundamental studies and innovative technology development.

This Special Issue welcomes the submission of original research and review manuscripts focusing on advancing the manufacturing of biologics with the opportunity to use a range of science and engineering approaches, including systems and synthetic biology, biochemistry, molecular biology, omics, statistical analysis, machine learning, computational biology, mechanical engineering, and many others.

Prof. Dr. Seongkyu Yoon
Dr. Sha Sha
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Biological therapy
  • Biomanufacturing
  • Product quality
  • Process control
  • Systems biology
  • Computation
  • Sensing technology
  • Statistical analysis
  • Machine learning
  • Biological engineering
  • Biochemistry
  • Mechanical engineering

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

14 pages, 1309 KiB  
Review
Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2
by Berina Sabanovic, Francesco Piva, Monia Cecati and Matteo Giulietti
Biology 2021, 10(2), 94; https://doi.org/10.3390/biology10020094 - 27 Jan 2021
Cited by 44 | Viewed by 6854
Abstract
Extracellular vesicles (EVs) are secreted from almost all human cells and mediate intercellular communication by transferring heterogeneous molecules (i.e., DNA, RNAs, proteins, and lipids). In this way, EVs participate in various biological processes, including immune responses. Viruses can hijack EV biogenesis systems for [...] Read more.
Extracellular vesicles (EVs) are secreted from almost all human cells and mediate intercellular communication by transferring heterogeneous molecules (i.e., DNA, RNAs, proteins, and lipids). In this way, EVs participate in various biological processes, including immune responses. Viruses can hijack EV biogenesis systems for their dissemination, while EVs from infected cells can transfer viral proteins to uninfected cells and to immune cells in order to mask the infection or to trigger a response. Several studies have highlighted the role of native or engineered EVs in the induction of B cell and CD8(+) T cell reactions against viral proteins, strongly suggesting these antigen-presenting EVs as a novel strategy for vaccine design, including the emerging COVID-19. EV-based vaccines overcome some limitations of conventional vaccines and introduce novel unique characteristics useful in vaccine design, including higher bio-safety and efficiency as antigen-presenting systems and as adjuvants. Here, we review the state-of-the-art for antiviral EV-based vaccines, including the ongoing projects of some biotech companies in the development of EV-based vaccines for SARS-CoV-2. Finally, we discuss the limits for further development of this promising class of therapeutic agents. Full article
(This article belongs to the Special Issue Advancing the Manufacturing of Biological Therapeutics and Vaccines)
Show Figures

Figure 1

Back to TopTop